Satellite Bio launched Wednesday with $110 million in previously undisclosed Seed and Series A investments led by aMoon Growth.

Three patients whose lower bodies were left completely paralyzed after spinal cord injuries were able to walk, cycle and swim using a nerve-stimulation device controlled by a touchscreen tablet, researchers reported on Feb. 7.

Johnson & Johnson settled most of the lawsuits the company faced by thousands of men who claimed the anti-psychotic drug Risperdal caused them to develop excessive breast tissue and disclosed that J&J recorded $800 million in expenses in connection with the agreement.

Severe Covid-19 may trick the immune system into producing so-called autoantibodies that have the potential to eventually attack healthy tissue and cause inflammatory diseases, researchers warned in a paper published in Nature Communications. Another study suggests that the virus that causes Covid-19 may be getting better at traveling into the air

Biogen reported positive topline results from the company’s Phase II CONVEY trial of vixotrigine for the treatment of small fiber neuropathy (SFN). 

AstraZeneca said on Aug. 26 a late-stage trial showed the company’s medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.

Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp.’s experimental heart therapy PRX004 in a deal that could be worth up to $1.23 billion, the companies said on July 12.

The U.S. drug regulator on June 29 declined to approve MediWound Ltd.’s topical burn treatment NexoBrid, sending the company’s shares tumbling in trading.

Retinal tissue was regrown in three patients with age-related macular degeneration with geographic atrophy or dry (atrophic) AMD in a Phase I/IIa study conducted by Lineage Cell Therapeutics.

Enzyvant Sciences resubmitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for the company’s tissue-based regenerative pediatric congenital athymia therapy RVT-802.